#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Canavan disease Extra-osseous Ewing's sarcoma Non-Hodgkin's lymphoma unspecified histology aggressive recurrent Graft versus host disease Cutaneous T-cell lymphoma recurrent Vascular malformation Pemphigus Kidney transplant rejection Acute graft versus host disease in intestine Erdheim-Chester disease Lung adenocarcinoma Cervix carcinoma Adenomatous polyposis coli Subdural haematoma Cortical dysplasia More trials…

    Learn about Rare Diseases

    Propionic acidaemia – Trials in Disease Mantle cell lymphoma stage II – Life with Disease Osteosarcoma – Life with Disease Aicardi-Goutieres syndrome Cystic fibrosis lung – Diagnostics Haemophilia Paroxysmal nocturnal haemoglobinuria Mucopolysaccharidosis III – Treatment Brain stem glioma – Treatment Carcinoid syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Betamethasone Dipropionate Rasagiline Depemokimab Mepivacaine Hydrochloride Fostemsavir Arsenic Trioxide Mps-214 TAGRAXOFUSP Solrikitug Estradiol Ecoo75 Labetalol Hydrochloride Levobupivacaine Hydrochloride Ribonucleic Acid K30 Gs-1427 Other Blood Products Tulmimetostat Clenbuterol Hydrochloride Msv/As Ucp2 More therapies…

    Learn about Your Condition

    Dyskinesia Breast angiosarcoma Multifocal motor neuropathy Angiosarcoma Foetal growth restriction Metabolic disorder Tourette's disorder Melanoma recurrent Antithrombin III deficiency Haemorrhagic stroke Ichthyosis Vulvovaginal pruritus Breast cancer Anal abscess Lymphatic malformation More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Breast cancer metastatic

  • Study on Cyclophosphamide for Patients with Advanced Breast Cancer with TP53 Mutations

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Breast cancer
    Investigated Drugs:
    • Cyclophosphamide
    Norway

  • Study of PF-07220060 and Letrozole for Postmenopausal Women with HR-Positive, HER2-Negative Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Breast cancer
    Investigated Drugs:
    • Pf-07220060 Monohydrate
    • Letrozole
    Belgium France Germany Italy Poland Slovakia +2

  • Study Comparing Oral Paclitaxel (DHP107) and IV Paclitaxel for Patients with Recurrent or Metastatic HER2 Negative Breast Cancer

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Breast cancer recurrent
    • Breast cancer metastatic
    • Human epidermal growth factor receptor negative
    Investigated Drugs:
    • Paclitaxel
    Hungary

  • Study of Durvalumab, Olaparib, and Fulvestrant for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer with Specific Genetic Alterations

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Breast cancer
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Goserelin Acetate
    • Durvalumab
    • Fulvestrant
    Belgium France Spain

  • Study of fulvestrant and palbociclib combination for postmenopausal women with hormone receptor-positive metastatic breast cancer who completed 5 years of hormone therapy or have new metastatic disease

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    Investigated Drugs:
    • Palbociclib
    • Fulvestrant
    Ireland Spain

  • Study on the Impact of Fluoroestradiol F-18 PET on Treatment for Patients with ER+ HER2- Metastatic Breast Cancer After First-Line Hormone Therapy Relapse

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • HER2 negative breast cancer
    • Hormone receptor negative HER2 positive breast cancer
    • Oestrogen receptor gene overexpression
    Investigated Drugs:
    • Fluoroestradiol F-18
    France
Previous Page
1 … 11 12 13 14
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!